Published by Coherent Market Insights
Posted on September 17, 2021
8 min readLast updated: January 20, 2026
Global Bioresorbable Vascular Scaffold Market
Bioresorbable vascular stents help prevent blockage by expanding the blood vessels, and get naturally disintegrated in the human body without any external intervention. These stents prevent inflammation that often leads to stent restenosis and thrombosis, and further eliminates the need for post-treatment involvements. Bioresorbable stents are superior in quality to the first and second generation stents, as they curb the need for dual antiplatelet therapies.
The global bioresorbable vascular scaffold market was valued at US$ 147.0 million in 2017, and is expected to exhibit a magnificent CAGR of 12.5% over the forecast period (2018-2026).
Request for Sample Copy of Report: https://www.coherentmarketinsights.com/insight/request-sample/2471
Increasing prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases to propel market growth
A bioresorbable vascular scaffold is used in the treatment of blockage of coronary and peripheral arteries, which are related to coronary heart disease, ischemic heart disease, and other cardiovascular diseases. High prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to propel demand for bioresorbable vascular scaffold, which in turn, would accelerate the global market growth. According to the World Health Organization (WHO), 2015, cardiovascular diseases is the first leading cause of morbidity and mortality worldwide, with around 17.7 million representing 31% of all global deaths in 2015, out of these deaths, an estimated 6.7 million were due to stroke and 7.4 million were due to coronary heart disease.
As reported by the American Heart Association, in 2018, approximately 92.1 million American adults suffered from some form of cardiovascular disease or the after-effects of stroke. Nearly 836,546 deaths in the U.S. were due to cardiovascular disease, which is about 1 of every 3 deaths. Direct and indirect costs in the treatment of cardiovascular diseases and stroke were estimated to amount to US$ 329.7 billion in 2018, which includes both health expenditures and lost productivity, in the U.S.
Furthermore, introduction of novel bioresorbable vascular scaffold, which help patients with cardiovascular diseases, is propelling growth of the bioresorbable vascular scaffolds market over the forecast period. For instance, in July 2016, Abbott received approval from the US Food and Drug Administration for Absorb GT1 bioresorbable vascular scaffold (BVS). The product fully resorbs over time and improves coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions.
However, complications such as damage to central veins, pulmonary complications, cardiac complications, device dysfunction, and catheter-related bloodstream infection are predicted to limit the adoption of bioresorbable vascular scaffolds, thereby hindering the global bioresorbable vascular scaffold market growth.
Get Flat USD 2000 OFF
Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/2471
Reasons to Purchase this Report:
Current and future of global Bioresorbable Vascular Scaffold Market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period.
The latest developments, market shares, and strategies that are employed by the major market players.
Increasing adoption of bioresorbable vascular scaffolds in North America is expected to boost market growth in the region
North America is expected to hold a dominant position in the global bioresorbable vascular scaffold market, owing to a rapid surge in the geriatric population, rising incidences of cardiac ailments, coronary & peripheral artery diseases, and increasing number of obese people in the region. According to the World Population Prospects, the number of persons aged 80 or over is projected to triple by 2050, from 137 million in 2017, to 425 million in 2050 in the U.S., while this age bracket is expected to more than double globally, rising from 962 million in 2017 to 2.1 billion in 2050.
Key Market Players
The major players operating in the global bioresorbable vascular scaffold market include Abbott, Cook Medical, Boston Scientific Corporation, B. Braun Melsungen AG, Medtronic Plc., Stentys SA, MAQUET Holding B.V. & Co. KG (Getinge AB), W.L. Gore & Associates, C. R. Bard, Inc., and Theragenics Corporation.
These companies are deeply focused on receiving regulatory approvals for their novel products to reduce the burden of blood stream infections associated with bioresorbable vascular scaffolds. For instance, in May, 2018, Pursuit Vascular, Inc., received U.S. FDA clearance for broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with bioresorbable vascular scaffolds.
Contact US
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Bioresorbable Vascular Scaffold Share Rise reach US$ 147.0 Mn till 2027 | Technology, Segmental Analysis, Current Trends, Top Competitive and Growth Register a CAGR of 12.5% appeared first on Gatorledger.
Global Bioresorbable Vascular Scaffold Market
Bioresorbable vascular stents help prevent blockage by expanding the blood vessels, and get naturally disintegrated in the human body without any external intervention. These stents prevent inflammation that often leads to stent restenosis and thrombosis, and further eliminates the need for post-treatment involvements. Bioresorbable stents are superior in quality to the first and second generation stents, as they curb the need for dual antiplatelet therapies.
The global bioresorbable vascular scaffold market was valued at US$ 147.0 million in 2017, and is expected to exhibit a magnificent CAGR of 12.5% over the forecast period (2018-2026).
Request for Sample Copy of Report: https://www.coherentmarketinsights.com/insight/request-sample/2471
Increasing prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases to propel market growth
A bioresorbable vascular scaffold is used in the treatment of blockage of coronary and peripheral arteries, which are related to coronary heart disease, ischemic heart disease, and other cardiovascular diseases. High prevalence of coronary heart disease, ischemic heart disease, and other cardiovascular diseases is expected to propel demand for bioresorbable vascular scaffold, which in turn, would accelerate the global market growth. According to the World Health Organization (WHO), 2015, cardiovascular diseases is the first leading cause of morbidity and mortality worldwide, with around 17.7 million representing 31% of all global deaths in 2015, out of these deaths, an estimated 6.7 million were due to stroke and 7.4 million were due to coronary heart disease.
As reported by the American Heart Association, in 2018, approximately 92.1 million American adults suffered from some form of cardiovascular disease or the after-effects of stroke. Nearly 836,546 deaths in the U.S. were due to cardiovascular disease, which is about 1 of every 3 deaths. Direct and indirect costs in the treatment of cardiovascular diseases and stroke were estimated to amount to US$ 329.7 billion in 2018, which includes both health expenditures and lost productivity, in the U.S.
Furthermore, introduction of novel bioresorbable vascular scaffold, which help patients with cardiovascular diseases, is propelling growth of the bioresorbable vascular scaffolds market over the forecast period. For instance, in July 2016, Abbott received approval from the US Food and Drug Administration for Absorb GT1 bioresorbable vascular scaffold (BVS). The product fully resorbs over time and improves coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions.
However, complications such as damage to central veins, pulmonary complications, cardiac complications, device dysfunction, and catheter-related bloodstream infection are predicted to limit the adoption of bioresorbable vascular scaffolds, thereby hindering the global bioresorbable vascular scaffold market growth.
Get Flat USD 2000 OFF
Buy-Now this research report: https://www.coherentmarketinsights.com/promo/buynow/2471
Reasons to Purchase this Report:
Current and future of global Bioresorbable Vascular Scaffold Market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period.
The latest developments, market shares, and strategies that are employed by the major market players.
Increasing adoption of bioresorbable vascular scaffolds in North America is expected to boost market growth in the region
North America is expected to hold a dominant position in the global bioresorbable vascular scaffold market, owing to a rapid surge in the geriatric population, rising incidences of cardiac ailments, coronary & peripheral artery diseases, and increasing number of obese people in the region. According to the World Population Prospects, the number of persons aged 80 or over is projected to triple by 2050, from 137 million in 2017, to 425 million in 2050 in the U.S., while this age bracket is expected to more than double globally, rising from 962 million in 2017 to 2.1 billion in 2050.
Key Market Players
The major players operating in the global bioresorbable vascular scaffold market include Abbott, Cook Medical, Boston Scientific Corporation, B. Braun Melsungen AG, Medtronic Plc., Stentys SA, MAQUET Holding B.V. & Co. KG (Getinge AB), W.L. Gore & Associates, C. R. Bard, Inc., and Theragenics Corporation.
These companies are deeply focused on receiving regulatory approvals for their novel products to reduce the burden of blood stream infections associated with bioresorbable vascular scaffolds. For instance, in May, 2018, Pursuit Vascular, Inc., received U.S. FDA clearance for broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with bioresorbable vascular scaffolds.
Contact US
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Bioresorbable Vascular Scaffold Share Rise reach US$ 147.0 Mn till 2027 | Technology, Segmental Analysis, Current Trends, Top Competitive and Growth Register a CAGR of 12.5% appeared first on Gatorledger.
Explore more articles in the Research Reports category
